little is known about the use and toxicity of antiadhesion substances such as sodium hyaluronatecarboxymethylcellulose.
i ntraperitoneal adhesions cause significant morbidity in patients who have undergone surgery. [1] [2] [3] [4] [5] adhesions are associated with pain, bowel obstruction, and infertility, and they increase the risk of operative injury in future procedures. [1] [2] [3] [4] [5] [6] it has been estimated that adhesive disease is responsible for two-thirds of bowel obstructions in developed countries.
1,2,4,5 of greater concern, the symptoms that result from adhesions are unpredictable and often persist over a patient's entire lifetime. 1 adhesions are particularly common after gynecologic and colorectal procedures with some studies suggesting that adhesions develop after 85% of gynecologic surgeries. [1] [2] [3] [4] [5] [6] adhesions develop after surgical trauma and result from mesothelial regeneration between damaged serosal surfaces. 1, 6, 7 Gentle tissue handling and attention to meticulous surgical technique may reduce, but cannot completely eliminate, the risk of postoperative adhesion formation. a number of interventions have been developed over the past 2 decades to reduce the risk of developing adhesions. 1, 6, 8 although pharmacologic strategies such as corticosteroids and anticoagulants have met with only limited success, barrier agents have received greater enthusiasm. 1, 6, 8 Barrier agents, either fluids or solid-phase membranes, prevent contact between denuded serosal surfaces to reduce adhesions. 1, 6, 8 a number of barrier substances, including hyaluronic acid, hyaluronate/carboxymethyl cellulose (ha-CmC) membrane, oxidized regenerated cellulose, polytetrafluoroethylene, and 4% icodextrin, have been marketed for general and gynecologic surgery. 1, 6, 8 to date, hyaluronic acids and ha-CmC have received the greatest attention. Recent meta-analyses have suggested that these agents decrease adhesion formation in patients undergoing gynecologic (oR = 0.31; 95% Ci, 0.19-0.51) as well as nongynecologic abdominal surgery (oR = 0.15; 95% Ci, 0.05-0.43). 1, 6 Despite potential efficacy in adhesion prevention, a number of potential safety concerns have arisen for ha-CmC including possible increased risk of abdominal-pelvic fluid collections and abscess formation. [9] [10] [11] [12] [13] [14] although antiadhesion substances including ha-CmC are widely marketed, little is known about the patterns of use of these agents in practice or the factors that influence use and toxicity. We performed an analysis to determine the patterns of use and safety of ha-CmC in patients undergoing gynecologic and colorectal surgery.
METHODS
Data Source the Perspective database (Premier, Charlotte, nC) was used. the Perspective database is a voluntary, fee-supported data set that was originally developed to measure quality and resource use. the database includes patients from more than 600 acute-care hospitals throughout the united states. 15 in addition to demographics, disease characteristics, and procedures, the database collects information on all billed services including the use of drugs and devices. the Perspective database has been previously validated and has been used in a number of outcomes studies. [16] [17] [18] Patients who underwent procedures coded as laparoscopic were not included in the analysis. We recorded concomitant procedures at the index operation including performance of adhesiolysis (iCD-9 54.5x, 59.1x, 65.8x, 59.02, 59.03) or small-bowel resection (iCD-9 45.6x). for women who underwent hysterectomy, we also recorded the performance of colectomy (codes as above) or rectosigmoid resection (iCD-9 48.5x, 48.6x). the use of haCmC was based on billing for any ha-CmC.
Clinical, Demographic, and Hospital Characteristics
Demographic data analyzed included sex (male or female), age (<60 or ≥60 years of age), race (white, black, or other), year of diagnosis, marital status (married or single), insurance (commercial, medicare, medicaid, or uninsured), and the presence of cancer (gynecologic cancer for women who underwent hysterectomy iCD-9 179-184.9 and colon cancer for patients who underwent primary colectomy iCD-9 153-153.9). Risk adjustment for comorbid conditions was performed by using the Charlson comorbidity index.
19 the iCD-9 coding to define the Charlson index as reported by Deyo and colleagues 20 was used. a number of hospital characteristics were also analyzed, including area (metropolitan, or nonmetropolitan), region (eastern, midwest, southern, or Western), size (<400, 400-600, or >600 beds), and teaching status (teaching, nonteaching). We also classified hospitals based on their individual case mix of patients who underwent hysterectomy and colectomy. the characteristics analyzed included the percentage of patients <60 years of age (<50 vs ≥50%), percentage of black patients (<20% vs ≥20%), percentage of medicaid/uninsured patients (<10% vs ≥10%), percentage of patients with commercial insurance (<50% vs ≥50%), and percentage of patients with >1 comorbidity (<40% vs ≥40%).
for each surgeon and hospital, we determined the total number of procedures performed during the study period. Because not all providers contributed data over the entire study period, we calculated annualized procedure volumes. the annualized procedure volume was estimated by dividing the total number of patients who underwent a procedure by the number of years a given surgeon or hospital contributed at least 1 procedure. the volumes were then divided to create 3 approximately equal tertiles of surgeon and hospital volume: low, intermediate, and high. 21, 22 separate volume estimates were determined for hysterectomy and colectomy. Statistical Analysis an initial analysis was performed to determine the characteristics of the hospitals within our data set that used ha-CmC. all hospitals that performed hysterectomy or colectomy were included in these analyses. hospital characteristics were compared by using χ 2 tests for any vs no ha-CmC use. a second analysis was then performed to determine the hospital characteristics associated with early uptake (first use of ha-CmC in or before 2004 compared with no use of ha-CmC or first use after 2004).
the initial hospital-level analysis identified 464 hospitals in which ha-CmC was used. Because surgeons in hospitals that never used ha-CmC may not have had access to the product, we limited all subsequent patient-level analyses to only those patients treated at hospitals that had reported ha-CmC use in at least 1 case. the characteristics associated with ha-CmC use were compared by using χ 2 tests. to determine the predictors of ha-CmC use, we developed multivariate mixed-effects log-binomial regression models.
23 these models included all of the patient and hospital characteristics as well as a random intercept for each hospital. Results are reported as relative risks with 95% Cis. separate models were developed for colectomy and hysterectomy.
to analyze the outcomes of interest and minimize selection bias, we performed a propensity score-matched analysis. the propensity score is the conditional probability that a patient will receive a given intervention, in this case ha-CmC. once estimated, the propensity score can be used to reduce bias through matching. 24-26 a propensity score was generated for each patient with the use of logistic regression models that included all of the clinical and demographic variables. the probabilities this analysis were used to generate a propensity score ranging from 0 to 1 for each patient. separate models were developed for patients who underwent hysterectomy and colectomy. Based on the propensity score, matched groups (2 controls to 1 case) were generated by using a matching algorithm with a caliper of 0.005. 24 the caliper is the largest distance allowed between 2 propensity scores to define a match. sensitivity analyses were performed matching different numbers of controls to cases, as well as using different caliper settings. separate propensity score models were developed for patients who underwent hysterectomy and colectomy. the characteristics of patients who received ha-CmC and those who did not after propensity matching were compared by using χ 2 tests. univariable regression was then performed to determine the association between haCmC use and the outcomes of interest. Despite propensity matching for the use of ha-CmC, a number of factors, such as perioperative complications that occur after haCmC placement, may also influence the outcomes of interest, such as abscess formation and bowel complications. to control for these confounding factors, multivariable logistic regression models were developed to determine the influence of ha-CmC use on the primary and secondary outcomes in the propensity-matched cohort. in addition to the use of ha-CmC, these models included the occurrence of intraoperative complications (bladder, ureteral, intestinal, bowel, or vascular injury or other operative injury), infectious complications (pneumonia, bacteremia, sepsis), medical complications (venous thromboembolism, myocardial infarction, cardiopulmonary arrest, renal failure, respiratory failure, shock, stroke), hemorrhage and transfusion, as well as factors that predispose patients to complications (age, comorbidity). all analyses were performed with sas version 9.2 (sas institute inc, Cary, nC). all statistical tests were 2-sided.
RESULTS
a total of 649,723 patients, including 382,355 who underwent hysterectomy and 267,368 who underwent colectomy, were identified. ha-CmC was used at least once by 464 (75.8%) of the 612 hospitals that performed procedures in our data set (table 1) . hospitals with a higher concentration of elderly patients, a lower concentration of black patients, a lower concentration of medicaid/uninsured patients, a higher concentration of patients with commercial insurance, and a higher concentration of patients with ≥1 medical comorbidity were more likely to use ha-CmC (p < 0.05 for all). similarly, teaching hospitals, hospitals in metropolitan areas, larger hospitals, and centers in the western u.s. were more likely to use ha-CmC (p < 0.05). similar trends were noted for early uptake (use in or before 2004) of ha-CmC, hospitals with a higher concentration of elderly patients, a lower concentration of medicaid/uninsured patients, a higher concentration of patients with commercial insurance, teaching hospitals, large hospitals, and centers in the south and west were more likely to incorporate ha-CmC early (p < 0.05). tables 2 and 3 display the characteristics of the unmatched and propensity-matched cohort of patients who underwent hysterectomy and colectomy. ha-CmC was used in 5.0% (19, 304) after propensity score matching and risk adjustment, ha-CmC use was not associated with abscess formation (RR = 0.97; 95% Ci, 0.84-1.12) in women who underwent hysterectomy. in the hysterectomy cohort, ha-CmC was associated with bowel obstruction (RR = 1.38; 95% Ci, 1.15-1.66) and ileus (RR = 1.68; 95% Ci, 1.59-1.78) (tables 5 and 6). among patients who underwent colectomy, ha-CmC use was associated with a 13% increased risk of abscess formation (RR = 1.13; 95% Ci, 1.08-1.17). in patients who underwent colectomy, ha-CmC was also associated with wound complications (RR = 1.19; 95% Ci, 1.09-1.30), bowel obstruction (RR = 1.13; 95% Ci, 1.07-1.19), ileus (RR = 1.14; 95% Ci, 1.10-1.18), reoperation (RR = 1.20; 95% Ci, 1.10-1.30), and peritonitis (RR = 1.13; 95% Ci, 1.07-1.19).
DISCUSSION
our findings suggest that ha-CmC use has gradually increased over the past decade for patients undergoing both hysterectomy and colectomy. Despite a number of retrospective studies and meta-analyses, use for both procedures remains <15%. We found no association between ha-CmC use and abscess formation in women who underwent hysterectomy, but did note a small but statistically significant association between ha-CmC and the development of abscesses in patients who underwent colectomy. a large number of studies have examined the efficacy of ha-CmC for the prevention of adhesions over the past decade. in addition to a number of institutional studies, several randomized trials and meta-analyses have suggested that ha-CmC may reduce the risk of postoperative adhesions. 1, 6, [27] [28] [29] [30] in one of the largest studies that included over 1700 patients who underwent intestinal resection, fazio and colleagues 28 noted that ha-CmC reduced the risk of small-bowel obstruction requiring reoperation. Despite the evidence supporting ha-CmC use, we noted that the use of ha-CmC for both hysterectomy and colectomy has been modest. in addition to more recent year of surgery, treatment by a high-volume surgeon appears to be one of the most important factors in use of ha-CmC for both procedures. Whereas patients with cancer undergoing hysterectomy were more likely to receive ha-CmC, the opposite was true for colectomy. safety concerns for antiadhesion products have been raised in a number of studies.
31-33 a trial of ferric hyaluronate of 700 patients undergoing open colorectal surgery was terminated after only 32 patients were enrolled. the investigators cited unacceptably high morbidity with cases of prolonged ileus, peritonitis, and anastomotic dehiscence in the study population. 31 the constellation of signs and symptoms has been termed "possible intergel Reaction syndrome" or "intergel Belly" and has led to legal actions and recall of the product in the united states. 32, 34 the potential association between ha-CmC use and abscess formation was highlighted by a meta-analysis in 2007.
14 although the study was criticized for a number of methodological issues, institutional studies, particularly for gynecologic surgery, have also identified an association between ha-CmC and postoperative fluid collections. [9] [10] [11] 13, [35] [36] [37] in an analysis of over 400 patients who underwent laparotomy for ovarian, tubal, or peritoneal cancer, leitao and colleagues noted intra-abdominal fluid collections in 8% of patients who received ha-CmC in comparison with 3% in those who did not receive haCmC. 13 the risk appeared greatest in those who underwent a cytoreductive procedure.
13 a retrospective report of 357 patients who underwent cytoreduction for ovarian cancer also noted an increased risk in pelvic abscess formation (oR = 2.66; 95% Ci, 1.21-5.86) in patients who received ha-CmC.
11 a recent Cochrane review reported no statistically significantly increased risk in abscess formation or overall morbidity in patients who received haCmC for nongynecologic surgery. 1 our findings are notable in that we identified an elevated risk of abscess formation in patients who underwent colectomy, but we found no association between ha-CmC use and abscess development in women who underwent hysterectomy. further, we noted an increase in ileus and bowel obstruction after both hysterectomy and colectomy with use of ha-CmC. a major concern of any study examining complications after ha-CmC use is the issue of unmeasured confounding. in the clinical setting, those patients at greatest risk for adhesive disease and at the highest risk for perioperative complications are likely the patients who are most likely to receive ha-CmC. although we attempted to minimize bias by using propensity score techniques and further adjusted our models for perioperative events, we cannot exclude the possibility that unmeasured factors influenced our findings. Previous work has suggested that the risk of abscess formation is highly dependent on the specific procedure and population under study. [11] [12] [13] although our study benefits from the inclusion of a large number of patients, we recognize several important limitations. We cannot exclude the possibility that we did not identify all patients who received ha-CmC. ha-CmC use was captured based on billing records, as has been previously described and validated for other drugs and devices using this database. 18 further, given the cost of these products, it is unlikely that many patients would have received ha-CmC without a charge. similarly, adverse outcomes such as abscess may have been underreported. although complications are underreported with the use of administrative data, a priori we analyzed only major perioperative complications that would likely have generated a claim and been recorded. in addition, underreporting of complications would likely have been balanced across the groups. along the same lines, with the use of administrative data, it is impossible to determine the timeframe of the occurrence of the complications under study. although we did not select patients who underwent a minimally invasive procedure, before the introduction of specific iCD-9 codes, these patients were likely coded as an open procedure and thus included in the analysis. although our data set samples hospitals from across the united states, we cannot exclude the possibility that these findings are not generalizable to other hospitals. We also recognize that patients who had disease-related complications such as an abscess before surgery were probably less likely to receive ha-CmC, which may have confounded our findings. last, the goal of our analysis was only to analyze short-term perioperative complications. the long-term effects of ha-CmC on intra-abdominal complications warrant further study.
similar to other studies, we noted a small but statistically significant increase in the rate of postoperative abscess formation as well as bowel complications. these data are of concern to practicing surgeons and raise the question of when ha-CmC should be used. it appears that much of the morbidity of ha-CmC use is context specific; for women undergoing gynecologic surgery, the risks appear to be greater for those with ovarian cancer than for other procedures. [11] [12] [13] for patients undergoing intestinal surgery, complications are particularly high when ha-CmC is applied directly to the anastomotic line. 27 for patients undergoing hysterectomy and colectomy, surgeons must weigh the risks and benefits of ha-CmC use carefully. large-scale studies to examine the safety of haCmC and define subgroups of patients at higher risk for complications are warranted.
